<DOC>
	<DOCNO>NCT01643200</DOCNO>
	<brief_summary>Evaluate safety feasibility Medtronic Zotarolimus stent improve erectile function males sub-optimal response PDE5i therapy due atherosclerotic lesion internal iliac and/or internal pudendal artery .</brief_summary>
	<brief_title>Safety Feasibility Zotarolimus Stent Treating Males With Erectile Dysfunction ( ED )</brief_title>
	<detailed_description>Stenting internal iliac and/or internal pudendal artery treatment mean improve sexual performance .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Males â‰¥ 18 year old stable heterosexual relationship minimum 6 month prior provide consent participate study ; The subject inform nature study , agree provision provide write informed consent approve Institutional Review Board ( IRB ) respective investigational site ; The subject successfully complete 4 week runin phase ; The subject mean PSV right leave cavernosal artery ; The subject angiographic evidence atherosclerotic stenosis internal iliac internal pudendal artery ; The subject able willing comply study requirement , include followup evaluation return investigational site ( ) require office visit . The subject life expectancy &lt; 12 month ; The subject erectile dysfunction associate nonvascular ( organic ) etiology ( i.e. , psychogenic , mixed , neurologic abnormality , untreated hormonal dysfunction , etc . ) ; The subject untreated depression hypertension ; The subject penile anatomical abnormality ( e.g . penile fibrosis Peyronie 's disease ) investigator 's opinion would impair sexual performance ; The subject 's partner , accord subject , complaint overall health cardiovascular mental health concern , specific sexual health problem sexual interest , sexual arousal , orgasm sexual pain issue ; The subject history myocardial infarction , stroke lifethreatening arrhythmia , unstable angina require hospitalization within 3 month prior enrollment actively receive nitrate therapy ; The subject know allergy contraindication component ( material , drug and/or polymer ) stent system , aspirin , heparin phenylepherine and/or sensitivity contrast medium adequately premedicated and/or allergic clopidogrel ticlopidine ; The subject poorly control diabetes mellitus ; The subject history bleeding diatheses coagulopathy refuse blood transfusion ; The subject receive chemotherapy treatment within 12 month prior enrollment ; The subject history prior radiation therapy pelvic region , radical prostatectomy cystectomy ; The subject untreated hypogonadism ; The subject know impaired renal function ; The subject take sildenafil vardenafil within 24 hour tadalafil within 36 hour prior enrollment study ; The subject participate another investigational device , biologic , drug study complete primary endpoint ( ) potential clinical interference beyond primary endpoint .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Male</keyword>
	<keyword>Zotarolimus</keyword>
	<keyword>Stent</keyword>
	<keyword>Stenosis</keyword>
	<keyword>Erection</keyword>
	<keyword>PDE5 Inhibitors</keyword>
</DOC>